Further study details as provided by Pediatric Partners of Ponte Vedra:

Primary Outcome Measures:

CogState touch screen measuring cognitive changes [ Time Frame: Data will be collected according to the following schedule: prior to treatment, following 5, 15, 25, and 40 HBOT treatments, as well as at post-treatment and 1 and 3-month follow-up ] [ Designated as safety issue: No ]

While HBOT is most often used in wound healing and serious infections, it has been utilized in treating various disorders, most notably in cerebral palsy (Liptak, 2005; Marois & Vanasse, 2003) and other conditions, including fetal alcohol syndrome (Stoller, 2005), brain injury (Rockswold, 1993), and stroke (Helms, 2005) (see Joiner, 2002 for a review). The rationale for using HBOT in participants with neurological and developmental disorders is to relieve hypoxia, which often accompany these conditions. This leads to improvements in microcirculation and relief of cerebral edema by vasoconstriction, therefore leading to decreases in the symptom characteristics.

HBOT is implemented in various dose pressures (ATA) by practitioners for the treatment of symptoms of autism, averaging around 1.3-1.5 atmospheres for one hour sessions, for a minimum of 40 sessions. The results of HBOT are presumed to be long-term, but systematic examination of both short-term and long-term effects is currently warranted.

Eligibility

Ages Eligible for Study:

6 Years to 75 Years (Child, Adult, Senior)

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

Yes

Criteria

Inclusion Criteria:

• Males and females from 6 to 75 years of age with typical cognitive function and no neurologic or psychological diagnoses potentially impairing cognitive function

No anticipated changes in treatment for the study duration (e.g., diet, nutrients)

No additional biomedical treatments started 6 weeks prior to enrollment

No changes in dietary management for 3 months prior to enrollment

Access to Pediatric Partners on a daily basis, or as necessary for the study participation

In addition, the participant must be:

Ambulatory or require minimum support walking

Able to sit still for 12 minutes or longer for the purposes of test administration

Adequate vision and hearing for the purposes of test administration, per parent

Able to read and understand basic instructions

Adequate arm-hand-finger coordination for computer use in outcome measurement

Medical disorders, if present, must be stable and controlled

Willing to participate by attending regularly scheduled appointments and completing the necessary measures

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00631215